Pfizer Limited Reports Strong Q3FY26 Results with 17.65% Revenue Growth
Pfizer Limited reported strong Q3FY26 results with total income of ₹683.24 crore, up 17.65% YoY from ₹580.75 crore. Net profit after tax increased 11.18% to ₹141.84 crore, while earnings per share grew to ₹31.01 from ₹27.89. For nine months ended December 2025, the company achieved total income of ₹2,037.65 crore and net profit of ₹522.61 crore, demonstrating consistent operational performance and market strength.

*this image is generated using AI for illustrative purposes only.
Pfizer Limited has delivered impressive financial results for the quarter ended December 31, 2025, demonstrating strong growth across key performance metrics. The pharmaceutical giant's quarterly performance reflects robust operational execution and market positioning in the competitive healthcare sector.
Financial Performance Overview
The company's financial results for Q3FY26 showcase significant improvement across multiple parameters. Total income reached ₹683.24 crore, marking a substantial 17.65% increase from ₹580.75 crore reported in the corresponding quarter of the previous fiscal year.
| Financial Metric | Q3FY26 | Q3FY24 | Growth (%) |
|---|---|---|---|
| Total Income | ₹683.24 crore | ₹580.75 crore | +17.65% |
| Net Profit (Before Tax) | ₹191.95 crore | ₹172.44 crore | +11.32% |
| Net Profit (After Tax) | ₹141.84 crore | ₹127.60 crore | +11.18% |
| Earnings Per Share | ₹31.01 | ₹27.89 | +11.19% |
Profitability Analysis
Pfizer Limited demonstrated strong profitability metrics during the quarter. Net profit before tax increased to ₹191.95 crore from ₹172.44 crore in the same period last year, representing an 11.32% growth. The company's net profit after tax stood at ₹141.84 crore, compared to ₹127.60 crore in Q3FY24, showing an 11.18% improvement.
The company's total comprehensive income for the quarter reached ₹143.71 crore, slightly higher than the net profit after tax, indicating positive other comprehensive income components. This comprehensive performance reflects the company's ability to generate value beyond core operational activities.
Nine-Month Performance
For the nine-month period ended December 31, 2025, Pfizer Limited maintained strong momentum with total income of ₹2,037.65 crore. The company achieved net profit after tax of ₹522.61 crore for the nine-month period, with earnings per share reaching ₹114.24.
| Nine-Month Metrics | FY26 (9M) |
|---|---|
| Total Income | ₹2,037.65 crore |
| Net Profit (Before Tax) | ₹706.85 crore |
| Net Profit (After Tax) | ₹522.61 crore |
| Earnings Per Share | ₹114.24 |
Capital Structure
The company maintained a stable capital structure with equity share capital of ₹45.75 crore, consisting of shares with a face value of ₹10 each. The consistent capital base provided a solid foundation for the company's growth initiatives and operational expansion.
Regulatory Compliance
The financial results were announced in compliance with Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The detailed quarterly financial results are available on stock exchange websites and the company's official website, ensuring transparency and accessibility for stakeholders and investors.
Historical Stock Returns for Maharashtra Seamless
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| +1.22% | +6.28% | +2.43% | -16.87% | -11.61% | +289.28% |


































